12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

Celgene disclosed in its 2Q12 earnings that it submitted an MAA to EMA to expand the label of multiple myeloma (MM) drug Revlimid lenalidomide to include treatment of myelodysplastic syndromes (MDS) in patients with 5q chromosomal...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >